# Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

> **NCT01794182** · PHASE2 · COMPLETED · sponsor: **Remedy Pharmaceuticals, Inc.** · enrollment: 86 (actual)

## Conditions studied

- Ischemic Stroke
- Malignant Edema

## Interventions

- **DRUG:** Glyburide for Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01794182
- **Lead sponsor:** Remedy Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-13
- **Primary completion:** 2016-04-04
- **Final completion:** 2016-04-04
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01794182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01794182, "Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01794182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*